Health TrialsbyHealthPanel

Bringing Medicines for HIV Prevention to a Family Planning Clinic

ConditionsHIVPrEP
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorWomen and Infants Hospital of Rhode Island

About this trial

The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are:

1. Do patients find it acceptable to be asked about, and offered, PrEP during their visit to a family planning clinic? 2. What things make it easier or harder to ask about PrEP in a family planning clinic setting? 3. What things make it easier or harder to begin PrEP in a family planning clinic setting?

Patient participants:

1. Will receive standardized counseling about PrEP. 2. Will have the opportunity to begin PrEP as part of their routine, ongoing care. 3. Will be asked to complete a survey about their experiences.

Physician participants:

1. Will receive standardized education about PrEP. 2. Will talk to patient participants about PrEP, and support patient participants who want to begin PrEP. 3. Will be asked to complete pre-and post-study surveys about their experiences. 4. May be asked to complete a post-study in-depth interview about their experiences.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Are age 16 or older

Are presenting for care at the Women and Infants Hospital of Rhode Island Family Planning Clinic

Speak English or Spanish

Have decisional capacity

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Patient participant screening

    Behavioral

    Patient participants will be provided with the standardized PrEP screening and initiation protocol.

  • Physician participant training

    Behavioral

    Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.

Treatment groups

83 Participants
are divided into 2 treatment groups
Group A: Patient ParticipantExperimental treatment 1 intervention
Group B: Physician ParticipantExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Acceptability of Intervention Measure

A validated measure of acceptability, administered via questionnaire. 4 Likert scale items. Item score range 1-5. Higher scores reflect higher acceptability.

Time frame
Up to hour 6 for patient participants; Up to month 12 for physician participants
2

Feasibility of Intervention Measure

A validated measure of feasibility, administered via questionnaire. 7-12 Likert scale items. Item score range 1-5. Higher scores reflect higher feasibility.

Time frame
Up to hour 6 for patient participants; Up to month 12 for physician participants
3

Intervention Appropriateness Measure

A validated measure of appropriateness, administered via questionnaire. 4 Likert scale items. Item score range 1-5. Higher scores reflect higher appropriateness.

Time frame
Up to hour 6 for patient participants; Up to month 12 for physician participants

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Women and Infants Hospital of Rhode Island

Lead sponsor

Advance RI CTR

Collaborator

Source ClinicalTrials.gov
Apply now